What is Medigene AG's contact information?

Medigene AG's contact information: +49892000330.

What industry does Medigene AG belong to?

Medigene AG is in the industry of: Research, Pharmaceuticals, Biotechnology, Healthcare.

What are Medigene AG's official social media profiles?

Medigene AG Linkedin Page Medigene AG Twitter Page

What tech stack does Medigene AG use?

Some of the popular technologies that Medigene AG uses are: WordPress, WordPress, MySQL.

What are Medigene AG's office addresses?

Medigene AG has 5 known office addresses: Lochhamer Str. 11, 82152 Planegg/Martinsried, Germany US DE Lochhamer Strasse 11, Planegg, BY, 82152, DE 11 Lochhamer Strasse, Planegg, Bavaria, Germany, 82152.

What is Medigene AG's estimated annual revenue?

Medigene AG's revenue is $20,000,000

What is Medigene AG's open headcount?

Medigene AG has no job postings yet.

What is the number of ad campaigns for Medigene AG?

Medigene AG has no advertisements yet.

What is the number of recent news articles about Medigene AG?

Medigene AG has 3 news articles.

Medigene AG - Pubrio Company Profile & Intent

Medigene AG

Germany · Research

Research

Pharmaceuticals

Biotechnology

Healthcare

Medigene AG is a biotechnology company based in Planegg/Martinsried, Germany, specializing in immuno-oncology. Founded in 1994, the company focuses on developing T cell receptor (TCR)-guided therapies to treat cancer. Medigene operates subsidiaries in the U.S. and Asia and is publicly listed on the Frankfurt Stock Exchange. The company utilizes its proprietary End-to-End (E2E) Platform to create TCR-based immunotherapies. This platform integrates technologies for TCR generation, optimization, and product enhancement, emphasizing specificity, sensitivity, and safety. Medigene's product offerings include TCR-T cell therapies, TCR-NK cell therapies, and TCR-T cell engagers. Notable lead candidates include MDG1015, targeting NY-ESO-1/LAGE-1a, and MDG2011, which targets the KRAS G12V mutation. Medigene aims to expand its pipeline of precision-targeted therapies for solid tumors, addressing significant medical needs in cancer treatment.